In this regard, STORM Therapeutics develops STM2457, a small-molecule inhibiting METTL3 presenting a potential therapeutic interest in the fight against leukemia [31] (https://www.stormtherapeutics.com/science/pipeline/, accessed on 4 May 2023). The gene discussed is METTL3; the disease is leukemia.